Sionna Therapeutics, Inc. (SION) Stock Statistics & Valuation Metrics

Sionna Therapeutics, Inc. has a market cap or net worth of $1.68B. The enterprise value is $1.63B.

Sionna Therapeutics, Inc. has 44,998,074 shares outstanding. The number of shares has decreased by -2.65% in one year.

Sionna Therapeutics, Inc.’s return on equity (ROE) is -0.25 and return on invested capital (ROIC) is -28.20%.

The current PE Ratio of Sionna Therapeutics, Inc. is ―. Sionna Therapeutics, Inc.’s PEG ratio is -0.64.

In the last 12 months, Sionna Therapeutics, Inc. had revenue of 0.00 and earned -75.27M in profits. Earnings per share was -1.88.

In the last 12 months, operating cash flow was -66.30M and capital expenditures -377.00K, giving a free cash flow of -66.67M billion.

Sionna Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Sionna Therapeutics, Inc. upcoming earnings date is Mar 19, 2026, Before Open (Confirmed).

Sionna Therapeutics, Inc. as a current ratio of 20.61, with Debt / Equity ratio of 2.83%

In the past 12 months, Sionna Therapeutics, Inc. has paid 0.00 in taxes.

Sionna Therapeutics, Inc. EV to EBITDA ratio is -18.05, with an EV/FCF ratio of -23.91.

Sionna Therapeutics, Inc. has $235.88M in cash and marketable securities with $8.68M in debt, giving a net cash position of $227.21M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Sionna Therapeutics, Inc. is $51.17, which is 11.43% higher than the current price. The consensus rating is Moderate Buy